AlphaCrest Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

AlphaCrest Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-120,900	Closed	-$2.44M	–	1485
2021 Q3	$2.44M	Buy	+120,900	New	+$3.34M	0.13%	214
2021 Q2	–	Sell	-7,900	Closed	-$202K	–	1392
2021 Q1	$202K	Buy	+7,900	New	+$202K	0.01%	1145
2020 Q4	–	Sell	-24,100	Closed	-$434K	–	1318
2020 Q3	$434K	Buy	24,100 +10,600	+79%	+$219K	0.05%	664
2020 Q2	$343K	Buy	+13,500	New	+$291K	0.06%	569

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

AlphaCrest Capital Management's DRNA Position: Q4 2021 in Review

AlphaCrest Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 120,900 shares — an estimated $2.44M sold.

AlphaCrest Capital Management first reported a position in DRNA in Q2 2020 and held it in 4 quarters. The position peaked at $2.44M in Q3 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

AlphaCrest Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
AlphaCrest Capital Management sold 120,900 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $2.44M.
AlphaCrest Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 4 quarters.
AlphaCrest Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $2.44M in Q3 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on AlphaCrest Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.